Fresenius Shares Rise After Deutsche Bank Upgrade Amid Broad European Corporate Earnings

German health‑care group Fresenius saw its share price jump around 1.6% to €42.39 after Deutsche Bank analysts reaffirmed a "Buy" rating with a €55 target, citing a solid second‑quarter outlook and the possibility of raising earnings guidance.

Swiss med‑device maker Medartis Holding AG announced a webcast for its 2026 half‑year results, with key executives Matthias Schupp and Peter Hackel set to present financial details.

Germany’s Commerzbank fell 3.25% to €36.66 after the federal government linked its approval of UniCredit’s takeover to three conditions, including preserving the Frankfurt headquarters and safeguarding Mittelstand financing.

U.S. construction equipment giant Caterpillar reported 2023 revenue of $67.1 billion and net profit of $10 billion, highlighting a strong order backlog and cash‑flow generation.

Johnson & Johnson disclosed a supply‑chain restructuring program costing $650‑750 million, aiming to streamline its Innovative Medicines division while continuing a $55 billion U.S. investment plan.

Swiss pharmacy retailer DocMorris received a UBS analyst’s upgrade from "Sell" to "Neutral" with a 12‑month target of CHF 10.40, praising cost control and market potential in Germany.

Bank of America maintained a "Buy" rating on Microsoft, setting a $500 price target and emphasizing Azure’s growth as critical ahead of the company’s fiscal‑quarter results.

Finland‑based Belimo Holding AG reported accelerated H1 2026 revenue growth of 29.6% in local currency, achieving CHF 676.4 million in sales and an EBIT margin of 22.5%.